Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.
Gwen M H E DackusKatarzyna JóźwiakElsken van der WallPaul J van DiestMichael HauptmannSabine SieslingGabe S SonkeSabine C LinnPublished in: Breast cancer research and treatment (2020)
The results of this population-based study are consistent with earlier randomized trials, demonstrating a non-significant difference in outcome for concurrently treated women compared to those who were treated sequentially, suggesting both options are justified.